AR070649A1 - Derivados de 1,3- dihidro -isoindol - Google Patents
Derivados de 1,3- dihidro -isoindolInfo
- Publication number
- AR070649A1 AR070649A1 ARP080103758A ARP080103758A AR070649A1 AR 070649 A1 AR070649 A1 AR 070649A1 AR P080103758 A ARP080103758 A AR P080103758A AR P080103758 A ARP080103758 A AR P080103758A AR 070649 A1 AR070649 A1 AR 070649A1
- Authority
- AR
- Argentina
- Prior art keywords
- hal
- atoms
- replaced
- mono
- nr6conr6r7
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/44—Iso-indoles; Hydrogenated iso-indoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/06—Antiasthmatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P17/00—Drugs for dermatological disorders
- A61P17/06—Antipsoriatics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P21/00—Drugs for disorders of the muscular or neuromuscular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/14—Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/04—Antibacterial agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/16—Antivirals for RNA viruses for influenza or rhinoviruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/20—Antivirals for DNA viruses
- A61P31/22—Antivirals for DNA viruses for herpes viruses
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/02—Antineoplastic agents specific for leukemia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
- A61P35/04—Antineoplastic agents specific for metastasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/04—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings directly linked by a ring-member-to-ring-member bond
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D403/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00
- C07D403/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings
- C07D403/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, not provided for by group C07D401/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
- C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
- C07D417/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a chain containing hetero atoms as chain links
Landscapes
- Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Public Health (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Oncology (AREA)
- Communicable Diseases (AREA)
- Molecular Biology (AREA)
- Neurology (AREA)
- Biomedical Technology (AREA)
- Pulmonology (AREA)
- Neurosurgery (AREA)
- Immunology (AREA)
- Dermatology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Urology & Nephrology (AREA)
- Cardiology (AREA)
- Endocrinology (AREA)
- Biotechnology (AREA)
- Heart & Thoracic Surgery (AREA)
- Psychiatry (AREA)
- Tropical Medicine & Parasitology (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Emergency Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Transplantation (AREA)
Abstract
Los derivados de 1,3-dihidro-isoindol de la formula (1) en donde R1 es A; R2 es A, (CH2)nAr o (CH2)nHet; R1 y R2 son, junto con el átomo de N al que están unidos, isoindolilo; R3 es H, Hal, OH, CN, NO2, C(O)H, NH2, COOH, COOA, CsCH, CsC-CH2OH, CONH2, CONHA, CONAA', SO2NH2, NHCONH2, X-A, X-(CH2)nAr o X-(CH2)nHet, en donde X es un enlace, -O-, -CO-, -CO2-, -C(O)NH, -C(O)NA', -S-, -SO-, -SO2-, SO2NH-, -SO2NA', -NH-, -NA'-, -NHSO2-, -NA'SO2, -NHCO-, -NA'CO-, -NHCONH- o -NA'CONH-; R3' es H, A, Hal, OA o CN; A, A' son en cada caso, de modo independiente entre sí, alquilo no ramificado o ramificado C1-10, en donde uno, dos o tres grupos CH2 o CH no adyacentes pueden estar reemplazados por O, S, SO, SO2, CO, NH, NR5 y/o por grupos -CH=CH y/o también 1-5 átomos de H pueden estar reemplazados por F, Cl, Br y/o R4, o cicloalquilo C3-7, A y A' son, junto con el átomo de N al que están unidos, también un heterociclo monocíclico saturado no sustituido o mono-, di- o trisustituido con Hal, A, (CH2)nOH, (CH2)nOA y/u =O (oxígeno del carbonilo), que puede contener otros 1 a 3 átomos de N, O y/o S; R4 es COOR6, CN, CONR6R7, NR6R7, NHCOR6, NHCOOR6, NR6CONR6R7 u OR6; R5 es cicloalquilo C3-7, cicloalquilalquileno C4-10, Alk o alquilo no ramificado o ramificado C1-6, en donde uno, dos o tres grupos CH2 o CH no adyacentes pueden estar reemplazados por O, CO, S, SO, SO2, NH y/o también 1-5 átomos de H pueden estar reemplazados por F y/o Cl; R6, R7 son en cada caso, de modo independiente entre sí, H o alquilo C1-5, en donde 1-3 grupos CH2 o CH no adyacentes pueden estar reemplazados por O, CO, S, SO, SO2, NH, NMe o Net y/o también 1-5 átomos de H pueden estar reemplazados por F y/o Cl, R6 y R7 son juntos también una cadena de alquileno con 2, 3, 4, 5 o 6 átomos de C, en donde 1-3 átomos de C no adyacentes pueden estar reemplazados por O, CO, S, SO, SO2, NH, NR5, NCOR5 o NCOOR5; Alk es alquenilo C2-6; Ar es fenilo, naftilo o bifenilo no sustituido o mono-, di-, tri-, tetra o pentasustituido con Hal, A, (CH2)nCN, (CH2)nAr', (CH2)nHet', (CH2)nOA, (CH2)nOH, S(O)mA, NO2, (CH2)NR6R7, NR5R6, CONR6R7 CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7 y/o NR6SO2R7; Ar' es fenilo, naftilo o bifenilo no sustituido o mono-, di- o trisustituido con Hal, A, CN, fenilo, OA, OH, S(O)mA, NO2, NR6R7, NR5R6, CONR6R7, CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7 y/o NR6SO2R7; Het es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, CN, Ar', Het' OA, OH, S(O)mA, NO2, NR6R7, NR5R6, CONR6R7, CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7, NR6SO2R7, =S, =NR8, =NR8R4 y/u =O (oxígeno del carbonilo); Het' es un heterociclo saturado, insaturado o aromático mono- o bicíclico con 1 a 4 átomos de N, O y/o S, que puede no estar sustituido o que puede estar mono-, di- o trisustituido con Hal, A, CN, Ar', OA, OH, S(O)nA, NO2, NR6R7, NR5R6, CONR6R7, CONR5R6, SO2NR6R7, SO2NR5R6, NR6COR7, NR6CONR6R7, NR6SO2R7, =S, =NR8, =NR8R4 y/u =O (oxígeno del carbonilo); R8 es H o A; Hal es F, Cl, Br o I; m es 0, 1 o 2, n 0, 1, 2, 3 o 4; así como sus derivados, sales, solvatos y estereoisomeros de utilidad farmacéutica, incluyendo sus mezclas en todas las proporciones. Son inhibidores de la HSP90 y pueden ser utilizados para preparar un medicamento para el tratamiento de enfermedades en las que la inhibicion, la regulacion y/o la modulacion de la HSP90 desempena un papel importante.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
DE102007041116A DE102007041116A1 (de) | 2007-08-30 | 2007-08-30 | 1,3-Dihydro-isoindolderivate |
Publications (1)
Publication Number | Publication Date |
---|---|
AR070649A1 true AR070649A1 (es) | 2010-04-28 |
Family
ID=40029128
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ARP080103758A AR070649A1 (es) | 2007-08-30 | 2008-08-29 | Derivados de 1,3- dihidro -isoindol |
Country Status (16)
Country | Link |
---|---|
US (1) | US8183279B2 (es) |
EP (1) | EP2181092B1 (es) |
JP (1) | JP5529739B2 (es) |
KR (1) | KR20100061817A (es) |
CN (1) | CN101790513A (es) |
AR (1) | AR070649A1 (es) |
AU (1) | AU2008295176B2 (es) |
BR (1) | BRPI0815059A2 (es) |
CA (1) | CA2697934C (es) |
DE (1) | DE102007041116A1 (es) |
EA (1) | EA201000362A1 (es) |
ES (1) | ES2532853T3 (es) |
IL (1) | IL204126A (es) |
MX (1) | MX2010002042A (es) |
WO (1) | WO2009030316A1 (es) |
ZA (1) | ZA201002217B (es) |
Families Citing this family (11)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2949467B1 (fr) | 2009-09-03 | 2011-11-25 | Sanofi Aventis | Nouveaux derives de 5,6,7,8-tetrahydroindolizine inhibiteurs d'hsp90, compositions les contenant et utilisation |
US9533002B2 (en) | 2012-05-25 | 2017-01-03 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (HSP) 90-β |
WO2014106019A2 (en) * | 2012-12-27 | 2014-07-03 | Philadelphia Health & Education Corporation, D/B/A Drexel | Novel antiviral agents against hbv infection |
WO2015188198A2 (en) | 2014-06-06 | 2015-12-10 | Berg Llc | Methods of treating a metabolic syndrome by modulating heat shock protein (hsp) 90-beta |
TW201617331A (zh) * | 2014-07-08 | 2016-05-16 | Viiv醫療保健英國有限公司 | 異吲哚啉衍生物 |
US10316167B2 (en) * | 2014-09-19 | 2019-06-11 | Plastipak Packaging | Oxygen scavengers, compositions comprising the scavengers, and articles made from the compositions |
US10464907B2 (en) * | 2016-01-29 | 2019-11-05 | Industry Academic Cooperation Foundation Keimyung University | Compound having HSP90 inhibitory activity or pharmaceutically acceptable salt thereof, and medical use thereof |
EP3478686B1 (en) | 2016-06-29 | 2020-04-15 | H. Hoffnabb-La Roche Ag | Novel dihydropyrrolopyrimidines for the treatment and prophylaxis of hepatitis b virus infection |
CN106366089B (zh) * | 2016-08-19 | 2019-06-11 | 爱斯特(成都)生物制药股份有限公司 | 二氢异吲哚衍生物及其类似物的制备方法 |
WO2018132769A1 (en) | 2017-01-12 | 2018-07-19 | University Of Kansas | Hsp90b n-terminal isoform-selective inhibitors |
WO2024044553A1 (en) * | 2022-08-21 | 2024-02-29 | University Of Notre Dame Du Lac | Use of (isoindolin-2-yl)(4-hydroxy-3-(isoindoline-2-carbonyl)phenyl)methanones in the treatment of tumor necrosis factor receptor-associated protein 1 dysfunction |
Family Cites Families (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5968921A (en) | 1997-10-24 | 1999-10-19 | Orgegon Health Sciences University | Compositions and methods for promoting nerve regeneration |
AU3378599A (en) | 1998-04-03 | 1999-10-25 | University Of Pittsburgh | Benzoquinoid ansamycins for the treatment of cardiac arrest and stroke |
EP1161231A2 (en) | 1999-03-12 | 2001-12-12 | THE UNITED STATES OF AMERICA, represented by THE SECRETARY, DEPT. OF HEALTH AND HUMAN SERVICES NATIONAL INSTITUTES OF HEALTH | Method of inhibiting a chaperone protein |
CA2429196A1 (en) | 2000-03-24 | 2001-10-04 | Duke University | Characterization of grp94-ligand interactions and purification, screening, and therapeutic methods relating thereto |
AU2001271567A1 (en) | 2000-06-29 | 2002-01-14 | Trustees Of Boston University | Use of geldanamycin and related compounds for prophylaxis or treatment of fibrogenic disorders |
EP1322325A4 (en) | 2000-07-20 | 2004-09-15 | Merck & Co Inc | INHIBITION OF PROCESSING AND REPLICATION OF HEPATITIS C VIRUS |
CA2417495C (en) | 2000-07-28 | 2013-04-30 | Sloan-Kettering Institute For Cancer Research | Methods for treating cell proliferative disorders and viral infections |
CA2440842A1 (en) | 2001-04-16 | 2002-10-24 | Eisai Co., Ltd. | Novel 1h-indazole compounds |
US7553979B2 (en) | 2001-11-09 | 2009-06-30 | Conforma Therapeutics Corporation | HSP90-inhibiting zearalanol compounds and methods of producing and using same |
RU2007106929A (ru) | 2004-07-27 | 2008-09-10 | Новартис АГ (CH) | Ингибиторы hsp90 |
TWI378090B (en) * | 2005-04-13 | 2012-12-01 | Astex Therapeutics Ltd | Pharmaceutical compounds |
US20090215742A1 (en) | 2005-05-03 | 2009-08-27 | Pfizer, Inc. | Amide resorcinol compounds |
-
2007
- 2007-08-30 DE DE102007041116A patent/DE102007041116A1/de not_active Withdrawn
-
2008
- 2008-07-28 WO PCT/EP2008/006198 patent/WO2009030316A1/de active Application Filing
- 2008-07-28 AU AU2008295176A patent/AU2008295176B2/en not_active Ceased
- 2008-07-28 CN CN200880104684A patent/CN101790513A/zh active Pending
- 2008-07-28 EP EP08785148.1A patent/EP2181092B1/de not_active Not-in-force
- 2008-07-28 JP JP2010522201A patent/JP5529739B2/ja not_active Expired - Fee Related
- 2008-07-28 KR KR1020107006638A patent/KR20100061817A/ko not_active Application Discontinuation
- 2008-07-28 BR BRPI0815059-1A2A patent/BRPI0815059A2/pt not_active Application Discontinuation
- 2008-07-28 EA EA201000362A patent/EA201000362A1/ru unknown
- 2008-07-28 US US12/675,410 patent/US8183279B2/en not_active Expired - Fee Related
- 2008-07-28 CA CA2697934A patent/CA2697934C/en not_active Expired - Fee Related
- 2008-07-28 ES ES08785148.1T patent/ES2532853T3/es active Active
- 2008-07-28 MX MX2010002042A patent/MX2010002042A/es not_active Application Discontinuation
- 2008-08-29 AR ARP080103758A patent/AR070649A1/es unknown
-
2010
- 2010-02-23 IL IL204126A patent/IL204126A/en not_active IP Right Cessation
- 2010-03-29 ZA ZA2010/02217A patent/ZA201002217B/en unknown
Also Published As
Publication number | Publication date |
---|---|
AU2008295176B2 (en) | 2013-05-02 |
EP2181092A1 (de) | 2010-05-05 |
ZA201002217B (en) | 2017-11-29 |
ES2532853T3 (es) | 2015-04-01 |
IL204126A (en) | 2015-07-30 |
JP2010536893A (ja) | 2010-12-02 |
BRPI0815059A2 (pt) | 2015-02-10 |
DE102007041116A1 (de) | 2009-03-05 |
WO2009030316A1 (de) | 2009-03-12 |
CA2697934C (en) | 2016-02-16 |
EP2181092B1 (de) | 2015-01-14 |
US8183279B2 (en) | 2012-05-22 |
AU2008295176A1 (en) | 2009-03-12 |
JP5529739B2 (ja) | 2014-06-25 |
CN101790513A (zh) | 2010-07-28 |
MX2010002042A (es) | 2010-03-15 |
CA2697934A1 (en) | 2009-03-12 |
US20100311745A1 (en) | 2010-12-09 |
KR20100061817A (ko) | 2010-06-09 |
EA201000362A1 (ru) | 2010-08-30 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
AR070649A1 (es) | Derivados de 1,3- dihidro -isoindol | |
AR067506A1 (es) | Derivados de quinazolinamida | |
AR054047A1 (es) | Derivados de fenilquinazolina | |
AR061735A1 (es) | Derivados de indazol, composiciones farmaceuticas y uso de los mismos | |
AR067082A1 (es) | Derivados de indazolamida, proceso de preparacion, medicamentos que los contienen y usos de los mismos, fundamentalmente, como agentes antitumorales y/o antivirales. | |
AR061009A1 (es) | 1,2-difenil-pirazoles i i como inhibidores de hsp90 | |
AR074418A1 (es) | Compuestos de benzonaftiridina, procedimiento de preparacion y su uso en el tratamiento de tumores | |
AR061010A1 (es) | Derivados de triazol i i | |
AR090602A1 (es) | AMIDAS CICLICAS Y HETEROCICLOS COMO INHIBIDORES DE MetAP-2 | |
AR052482A1 (es) | Derivados de triazol como inhibidores de hsp90 | |
AR081828A1 (es) | Compuestos de biguanida y su uso para el tratamiento del cancer | |
AR050454A1 (es) | 1,5-difenil-pirazoles. | |
AR073055A1 (es) | Derivados biciclicos de triazol | |
AR082726A1 (es) | Derivados de triazolopirazina | |
AR078979A1 (es) | Derivados de triciclo pirazol amina | |
AR074493A1 (es) | Derivados de quinazolinamida | |
AR057332A1 (es) | Tienopiridinas, procedimientos de obtencion y composiciones farmaceuticas | |
AR080803A1 (es) | Derivados de 3,4-dihidro-1h-benzo[b][1,6]naftiridina, composiciones farmaceuticas que los contiene, procedimiento para prepararlos e intermediarios del mismo, y uso de los compuestos en el tratamiento de canceres y enfermedades autoinmunes e inflamatorias. | |
AR072098A1 (es) | Derivados de pirrolidina como inhibidores de metap-2 | |
AR066892A1 (es) | Derivados de benzoxazolona, proceso, medicamento, uso para tratar tumores y kit | |
AR064010A1 (es) | Inhibidores de la actividad de la akt | |
AR078313A1 (es) | Derivados de piridinil-imidazolona inhibidores de quinasas pi3k,composiciones farmaceuticas que los comprenden, metodo para prepararlos y uso de los mismos en el tratamiento de enfermedades autoinmunes e inflamatorias, entre otras | |
AR056986A1 (es) | Aza heterociclos como inhibidores de quinasas. procedimiento de obtencion y composiciones farmaceuticas | |
AR089944A1 (es) | Derivados de tetrahidro-quinazolinona | |
AR072192A1 (es) | Derivados de tiazolil-piperidina |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FB | Suspension of granting procedure |